Elevara Medicines
Immunology & Inflammation Therapeutics · Biotechnology
1 public contract won
$39kPublic contracts won1 public contract
Lately:$39k won in the last 12 monthsFollow changes →
Facts
as of Nov 20, 2026Elevara Medicines is a clinical-stage biotech. ELV001 targets fibroblast-like synoviocytes and synergizes with DMARDs to achieve clinical remission in RA.
- Employees
- 51-200estimated range
- Website
- elevara.com
These are the key facts about Elevara Medicines on Alion as of Nov 20, 2026. The latest round is Series A of $70M, announced in 2025.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Funding
Full ledger, 1 record →Elevara Medicines has $70M paid in by investors, lenders and donors.
$70MPaid in
Money innewest first
$70MPaid
Money by yearUSD, rounds and grants
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Products
1 public contract won, $39k in all. $39k of it in the last 12 months.
Biggest buyers1 · $39k
Fakultní nemocnice v Motole
Czech Republic · 1 public contract
$39k
Milestones
Raised a round Series A $70M
Oct 21, 2025
Website went live first capture in the Wayback Machine
Jan 2011
Sources: the outlets named on each headline, each story once
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
